Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3019793 | Revista Española de Cardiología Suplementos | 2006 | 10 Pages |
Abstract
Treatment of non-ST-segment elevation acute coronary syndrome (NSTEACS) is based on anticoagulant and antiplatelet therapy along with coronary revascularization. Numerous studies have shown that an invasive strategy involving early coronary angiography and revascularization provides the best clinical outcome in high-risk patients. Associated medical treatment can change both disease prognosis and the result of coronary revascularization. To date, treatment with aspirin, clopidogrel and (unfractionated or low-molecular-weight) heparin is considered standard therapy for most patients with NSTEACS, with glycoprotein IIb/IIIa inhibitors being given to high-risk patients. However, there is still some uncertainty about treatment outcomes, timing and dosage when clopidogrel is given with a glycoprotein IIb/IIIa inhibitor. In addition, the better clinical results obtained with fondaparinux compared with enoxaparin, and the reduction in bleeding observed with bivalirudin relative to that seen with combination treatment with heparin and glycoprotein IIb/IIIa inhibitors, as reported in two recent studies, necessitate the re-evaluation of current treatment for NSTEACS.
Keywords
SECHBPMACCAntiagregantesHnfAntiplatelet therapyEstrategia invasivaSCASESTSociedad Europea de CardiologíaSociedad Española de CardiologíaInfarto agudo de miocardioESCsíndrome coronario agudo sin elevación del segmento STAnticoagulantesIAMheparina no fraccionadaHeparina de bajo peso molecularAnticoagulantsAmerican College of Cardiology
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
José Juan Gómez de Diego, Héctor Bueno Zamora,